---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-006813"
form_type: "8-K"
ticker: "CGTX"
cik: "0001455365"
company_name: "COGNITION THERAPEUTICS INC"
filed_at: "2026-01-27T23:59:59+00:00"
generated_at: "2026-05-16T07:29:38.942814+00:00"
event_type: "regulatory"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Cognition Therapeutics completes Type C FDA meeting for zervimesine in DLB; discusses Phase 2b endpoints

## Summary
- Type C meeting with FDA held on Jan 21, 2026 for zervimesine (CT1812) in dementia with Lewy bodies.
- Discussed clinically meaningful endpoints for proposed Phase 2b study in mild-to-moderate DLB.
- FDA meeting minutes expected later this quarter; no specific outcome disclosed.
- Zervimesine is an oral once-daily investigational drug targeting Aβ and α-synuclein toxicity.

## SEC filing metadata
- accession: 0001104659-26-006813
- form_type: 8-K
- ticker: CGTX
- cik: 0001455365
- company_name: COGNITION THERAPEUTICS INC
- filed_at: 2026-01-27T23:59:59+00:00
- event_type: regulatory
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1455365/000110465926006813/0001104659-26-006813-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1455365/000110465926006813/tm264096d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-006813
- JSON: https://secwatch.observer/filing/0001104659-26-006813.json
- Plain text: https://secwatch.observer/filing/0001104659-26-006813.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.